I am diabetic

Takeda is continuously committed to providenovel treatment options in cardiovascular/diabetes franchises

OSAKA, Japan, June 18, 2007 — Takeda Pharmaceutical Company Limited (“Takeda”) announced today that it has terminated the development of a fixed dose combination product of Actos®(pioglitazone HCl), a treatment for type 2 diabetes, and Takeda’s novel investigational drug TAK-536, an angiotensin receptor blocker. The phase 3 study of this combination product has been conducted in the U.S.

Takeda found out that an improvement in pharmaceutical formulation is needed for the fixed combination of Actos® and TAK-536, and has been reviewing its overall development projects in the franchises of cardiovascular and diabetes, while suspending that phase 3 study. As a result of this review, Takeda has reached a conclusion that it is optimal to prioritize projects other than Actos® + TAK-536 in order to provide novel treatment options as early as possible.

Takeda is continuously committed to enhance its cardiovascular and diabetes franchises by earliest possible launching of our investigational compounds such as SYR-322 for diabetes, TAK-475 for hypercholesterolemia, TAK-491 for hypertension and others, and by maximizing value of these investigational compounds as well as existing products such as Actos® and candesartan cilexitil (Blopress®, Amias®, Kenzen®, etc.).
Product Description

Most important information about Actos

Pharmacokinetics

Side Effects

More information about ACTOS (Pioglitazone):

FDA Alert

Actos Benefits Recent Heart-Attack Patients with Diabetes

Actos found to improve glucose control and lipid profiles

Takeda Revises Actos (pioglitazone HCl) Prescribing Label

New Analyses Show Actos Reduced Risk of Secondary Stroke by Almost 50 Percent

ACTOS (Pioglitazone) Combination Therapy

Submission of an Application for an additional Indication of Actos in Japan; Concomitant Therapy with Biguanides for Type 2 Diabetes

Takeda Wins Patent Infringement Litigation on Appeal Against ANDA Filers for Generic Actos

Diabetes Drugs Increase Risk of Heart Failure, Research Shows

To buy ACTOS click HERE: My Family Drugstore

Tags: Actos (Pioglitazone), Conditions & Treatments, Medications, Type 2 Diabetes

This entry was posted on Wednesday, December 19th, 2007 at 6:47 pm and is filed under Actos, Medications, Type 2 Diabetes. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.